Introduction
Burkitt lymphoma (BL) is a highly aggressive B-cell NonHodgkin lymphoma (NHL). It was the first tumor which was discovered to be associated with a viral infection (Epstein-Barr virus) and a chromosomal translocation which activates an oncogene (c-MYC). The BL and Burkitt leukemia is considered to be the part of the same disease spectrum. [1] WHO describes three distinct clinical forms of BL: endemic (African), sporadic (nonendemic), and immunodeficiency-associated. [1] BL is predominantly a disease of childhood, but it is also seen in the adult population. The diagnostic and therapeutic principles of BL in the adult are an extension of those used in the pediatric population.
The challenges of diagnosis and treatment of an aggressive lymphoma, like BL, is unique in low-income and resource-limited settings. The paucity of an adequate molecular diagnostic facility, trained hematopathologist, and limited access to health facility is an impediment in the adequate care of these patients. The data of the outcome of these patients from the low-income countries are sparse. Therefore, we, hereby present our experience of treating patients with BL with a uniform chemotherapy protocol from a tertiary care center in North India.
Materials and Methods

Patient information
We have retrospectively reviewed the case records of patients with BL registered in our clinics. The database included search from the digital records and case files of patients with a diagnosis of BL. We identified 22 cases of adult BL (age ≥18 years) during 2011-2017. Eighteen patients received cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, disease based on Modified Cheson lymphoma response evaluation criteria. The overall response rate (ORR) was calculated including CR and PR. [2] The time period from the beginning of the treatment to the date of death from any cause or to the date of the last follow-up was defined as overall survival (OS). Progression-free survival (PFS) was defined as the time from the beginning of treatment to disease progression or relapse.
Statistical analysis
Statistical analysis was done using IBM SPSS version 20. The Chi-square test was used to analyze the correlation between treatment regimen and achievement of response to therapy. Survival was calculated by Kaplan-Meier analysis and factors significantly affecting the survival outcomes were analyzed by Cox's proportional hazard method. Statistical significance was defined as P < 0.05.
Results
Patient characteristics
The median age at presentation was 38 years (19.0-64.0). Elderly patients (Age >60 years) constituted 11% of our study population. The majority of patients were male, with the male to female ratio being 3.5:1. The median duration of symptom duration before the presentation was 2 months (0.2-6 months). Extranodal involvement was seen in all the cases, the bone marrow was most common extranodal (9/18 [50%] Information on fluorescence in situ Hybridization (FISH) for c-MYC (8q24) gene was available in 5/18 (27.7%) cases; of which 2/5 (40%) cases were t (8, 14) positive while 2/5 (40%) cases did not reveal MYC gene rearrangement, one of these patients was tested only for t (8, 14) and turned out to be negative.
Four patients underwent an initial surgery and diagnosis of BL was confirmed on histopathological examination of the surgically resected specimen. Two patients presented with acute intestinal obstruction and underwent exploratory laparotomy, biopsy, and diversion colostomy. One of the patients presented with ileocecal mass and underwent right hemicolectomy. The 4 th patient presented with bilateral adnexal mass and omental deposits; she underwent exploratory laparotomy with total abdominal hysterectomy with bilateral salpingo-oophorectomy along with right hemicolectomy.
Treatment and outcome
Four patients were given prephase chemotherapy with cyclophosphamide and dexamethasone. Two patients initially received one cycle of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone), each in view of the delay in the confirmed diagnosis of BL. All the 18 patients included in this study were treated with a uniform protocol using CODOX-M/ *with granulocyte colony stimulating factor support till absolute neutrophil count > 1000/µl R-CODOX-M=Rituximab-cyclophosphamide, vincristine, doxorubicin, methotrexate, R-IVAC=Rituximab--ifosfamide, etoposide, cytarabine IVAC, of these 12 (66.6%) patients received rituximab. The ORR and complete response (CR) rate was 77.8% and 66.7%, respectively. In the subgroup of patients who received Rituximab RCODOX-M/IVAC (RCODOX-M/IVAC), the ORR, and CR rate was 75.0%, and 66.6% respectively while the ORR and CR rate in the CODOX-M/IVAC subgroup was 83.3.0% and 66.6%, respectively. Five (27%) patients had a progression of disease while on therapy, of these two patients developed new-onset cranial nerve palsy and on evaluation was found to have CNS disease along with nodal and medullary involvement. Of the other three patients, one patient developed new skin lesions and the other developed fulminant hepatic failure, both these patients were on evaluation confirmed to have disease progression. One patient with Burkitt leukemia had persistent bone marrow involvement despite therapy. All these five patients succumbed to their illness.
One patient had a partial response after completion of treatment; he received radiotherapy (36 Gy/20#) to residual disease. He achieved a CR after completion of radiotherapy.
Out of 18 patients on CODOX-M/IVAC, 14 high-risk patients and one low-risk patient received all 4 cycles and 3 cycles, respectively, i.e., 83.3% patients were able to complete scheduled treatment. Three high-risk patients received only 3 cycles as they had disease progression.
Toxicity
In our study, 16 (88.8%) patients had grade 3/4 neutropenia, 14 (77.7%) had grade 3/4 thrombocytopenia, 12 (66.6%) patients had febrile neutropenia, and 12 (66.6%) patients had grade 3/4 anemia. Of the nonhematologic toxicity, mucositis was the most significant toxicity, 6 (33.3%) patients developed grade 3/4 mucositis. The other nonhematologic grade 3/4 toxicity was diarrhea (15%) and transaminitis (5%).
Survival
The median event-free survival (EFS) and OS were not reached in our cohort. 
Discussion
This is the first case series describing the treatment outcome of the patients of BL using a uniform protocol from India. In our series, the median age of patients was 38 (19-64), while 2/18 (11%) patients were elderly (age >60 years). The patients were predominantly male (3.5:1). These findings are consistent with other case series. [3] [4] [5] In some series, a higher median age (44-58 year) has also been reported. [6, 7] Two earlier studies from India have reported the median age of presentation to be 22 years and 6.5 years with BL comprising 3.5% and 3% of all NHL, respectively. [8, 9] However, in these two studies, pediatric BL cases were also included in this study.
In the present study, the patients have a higher frequency of B-symptoms (66.6%), a higher proportion of advanced disease (77.8%), bone marrow involvement (50%), and Burkitt leukemia (22%) subtype. CNS involvement was not seen in our case series. The majority of the patients in our study were high risk (94.5%) and bone marrow being the most common extranodal site (50%) followed by GI tract (44.4%). Studies have reported bone marrow and central nervous system (CNS) involvement in 30%-38% and 13%-17% of adults, respectively. [3, 10, 11] In our study, all 18 patients received CODOX-M/IVAC regimen out of them, 12 received rituximab. The ORR and CR rate in our population was 75% and 66.6%, respectively. The 1-year EFS and OS was 76% and 81.1% respectively with a median follow-up of 15.6 (2.5-49.2) months. It is interesting that all patients who achieved CR at the end of treatment are disease free and surviving till the last follow-up. This supports the fact that though BL is an aggressive disease, once patients successfully complete treatment the long-term outcomes are good. The results of our study are comparable to the outcome of other studies using this protocol [3, 4, 12, 13, 17] [ Table 3 ]. All of these trials used a risk-adapted approach. Two-year EFS and OS varied from 64%-92% and 67%-73%, respectively in these studies. The Dosing of CODOX-M/IVAC has varied slightly between these studies. Other regimens such as Cancer and leukemia Group B, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), Rituxmab-HyperCVAD, Lymphomes Malins B (LMB) reported 2-year EFS and OS varied from 61% to 74% and 49% to 78%, respectively. [6, 7, 14] Dunleavy et al. reported a freedom from progression of 95% and OS of 100% at a median follow-up 86 months with DA-EPOCH regimen with rituximab. [15] The impact of rituximab has not been well studied in BL. Few studies reported 3-year EFS and OS in the rituximab-containing arms at 74%-76% and 77%-82% [16] [17] [18] [ Table 4 ].
Bone marrow involvement (P = 0.01) and female gender (P = 0.01) were significantly related to poor OS. The association of poor OS with female gender could be a chance association in view of a small sample size and relatively shorter follow-up. The grade 3/4 myelosuppression was universal CODOX-M/IVAC regimen, and it was the most common toxicity in our series. However, despite significant toxicity related to this regimen, the protocol completion rate in our series was 83.3%, which is comparable with western literature. [12, 18] There were no toxic deaths in this case series.
A large proportion of our patients were diagnosed of having BL based on morphology and immunohistochemistry. The molecular evidence through FISH was available in only five (27%) patients. In our resource-limited setting, the availability of FISH for MYC rearrangement hampers adequate molecular diagnosis of these patients.
Our study is limited by its small sample size, short follow-up, and retrospective study design. Despite, of these limitations, it gives us a window of opportunity to see the outcomes and toxicity of our patients who are treated with aggressive chemotherapy protocol like CODOX-M/IVAC.
Conclusion
Our patients of BL treated with CODOX-M/IVAC protocol are able to complete treatment despite significant toxicity. The outcomes of these patients are comparable to those in the western population. The bone marrow involvement at baseline was found to be a poor outcome predictor in our series which needs verification in larger series.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest. [3] CODOX-M/IVAC 52 35 High risk 77% 5 2 years EFS 65% 2 years OS 67% Mead et al. [4] CODOX-M/IVAC 53 37 High risk 79% 9 2 years EFS 64% 2 years OS 67% Magrath et al. [12] CODOX [6] CALGB regimen 105 44 IPI ≥3, 47% 7 2-year EFS 74% 3-year OS 58% Thomas et al. [7] Hyper CVAD 26 58 High LDH 70% 5 3-year CCR 61% 3-year OS 49% Diviné et al. [14] LMB regimen 72 33 High LDH 60% 0 2-year EFS 65% 2-year OS 70% Dunleavy et al. [15] DA-EPOCH 19 25 High LDH 37% 0 EFS 95%** OS 100%** Ribrag et al. [16] LMBA regimen With R Without R 128 129 47 High LDH 75% 9 7 3-year EFS 75% 62%
3-year OS 83% 70% Thomas et al. [18] R-hyper CVAD 31 46 High LDH 100% and radiological response sustained until December 2015. Serial CT scan done thereafter showed gradual radiological progression at single disease site. Crizotinib was continued as she remained asymptomatic. In July 2016, ceritinib was started in view of a significant increase in radiological burden of disease.. There was clinical and radiological progression of disease within 2 months of therapy. She began chemotherapy with pemetrexed-carboplatin.
In June 2017, she had new-onset pleural effusion. Alectinib 300 mg twice daily was started as third-line TKI. There was clinical benefit with no reported toxicity on subsequent follow-up. By RECIST criteria, she had partial response at 2 months which was sustained until December 2017. She presented after 6 months of therapy with alectinib with worsening cough and breathlessness. CECET scan confirmed radiological progression [ Figures 1-3 ]. Interestingly, she was never symptomatic for CNS disease despite failure of crizotinib and alectinib. She is presently planned for lorlatinib.
This case highlights the utility of second-generation TKI in ALK-positive NSCLC, especially in crizotinib refractory NSCLC. She tolerated crizotinib with sustained clinical benefit of 14 months. Ceritinib, her subsequent line of therapy, failed to control disease with progression within 2 months of initiation. With this background, alectinib has shown remarkable active in controlling an innately resistant disease for more than 6 months with no reported toxicity. Acquired mutations in ALK gene and P-glycoprotein overexpression have been reported mechanisms of crizotinib and certinib resistance which are overcome by alectinib. As our patient was unwilling for repeat biopsy, we were unable to identify resistant pathways which may help us choose from thirdgeneration TKI. [2] Two single-arm phase 2 studies (Shaw et al. and Ou et al.) [1, 3] evaluating alectinib in crizotinib-resistant disease showed PFS of 8.1 and 8.9 months and duration of response of 13·5 and 11.2 months, respectively. However, our patient had a PFS of only 6 months with alectinib.
In conclusion, sequential ALK suppression despite progression on TKI is the key to managing patients with ALK + NSCLC. Despite a shorter PFS than reported in literature, our patient had response to alectinib after two prior lines of ALK inhibitors. Future research should be directed at identifying mechanisms of resistance to ALK inhibitors which can help us choose the most appropriate TKI for our patients.
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